We propose to establish an AIDS Clinical Trials Unit at Yale University School of Medicine for people living with HIV disease in the City and County of New Haven and the State of Connecticut. This proposal represents an alliance between a small city with a major HIV epidemic and a renowned University with great scientific and clinical strength. The proposed assembles the expertise, experience, resources and commitment of scientists, clinicians and community members, and focuses them on the development and implementation of clinical trials of new therapies for HIV disease. It consists of a clinical core and five optional components in the areas of core virology, core pharmacology, developmental virology, developmental pharmacology and additional developmental research. We anticipate recruiting and enrolling 100 people with HIV disease during the first year of funding. The particular strengths of this application are: (1) The large population of people with HIV disease in New Haven and surrounding areas, which reflects the demography and risk profile of populations previously underrepresented in clinical trials. (2) The existence of over 1600 people with HIV disease who are known to the health care system and are currently receiving HIV related primary clinical care at 8 sites in New Haven and are available for enrollment in clinical trials. (3) The small size of New Haven, close proximity and already existing clinical relationships among these clinical sites which include a NIDA funded TRU, NIAID funded CPCRA, a NICHD funded clinical trials unit and a GCRC. (4) The experience of the PI and other study personnel in the successful performance of large scale studies of HIV disease in women, intravenous drug users and people of color. (5) The active participation of an already organized and broadly representative Community Advisory Board, drawn from the New Haven Mayor's Task Force on AIDS. (6) The presence and participation of a superior diagnostic virology laboratory which currently serves as the national reference laboratory for the VA Hospital system. (7) The expertise of renowned scientists in the areas of pharmacology and molecular pharmacology of antiretroviral agents. (8) Expertise in the areas of statistical and data management of clinical trials, host responses to infectious agents and patient health related behavior.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI032766-02
Application #
3547969
Study Section
Special Emphasis Panel (SRC (35))
Project Start
1992-04-01
Project End
1996-01-31
Budget Start
1993-02-01
Budget End
1994-01-31
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Yale University
Department
Type
Schools of Medicine
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Landry, M L; Stanat, S; Biron, K et al. (2000) A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 44:688-92
McCance-Katz, E F; Rainey, P M; Jatlow, P et al. (1998) Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr Hum Retrovirol 18:435-43
Ickovics, J R; Meisler, A W (1997) Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol 50:385-91
Landry, M L; Cohen, S; Huber, K (1997) Comparison of EDTA and acid-citrate-dextrose collection tubes for detection of cytomegalovirus antigenemia and infectivity in leukocytes before and after storage. J Clin Microbiol 35:305-6
Japour, A J; Lertora, J J; Meehan, P M et al. (1996) A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. J Acquir Immune Defic Syndr Hum Retrovirol 13:235-46
Griffith, B P; Brett-Smith, H; Kim, G et al. (1996) Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J Infect Dis 173:1252-5
Wetherill, P E; Landry, M L; Alcabes, P et al. (1996) Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease. J Acquir Immune Defic Syndr Hum Retrovirol 12:33-7
Skalski, V; Liu, S H; Cheng, Y C (1995) Removal of anti-human immunodeficiency virus 2',3'-dideoxynucleoside monophosphates from DNA by a novel human cytosolic 3'-->5' exonuclease. Biochem Pharmacol 50:815-21
Piras, G; Dutschman, G E; Im, G J et al. (1995) Action of uracil analogs on human immunodeficiency virus type 1 and its reverse transcriptase. Antimicrob Agents Chemother 39:539-41
Landry, M L; Ferguson, D; Cohen, S et al. (1995) Effect of delayed specimen processing on cytomegalovirus antigenemia test results. J Clin Microbiol 33:257-9

Showing the most recent 10 out of 13 publications